跳至主要内容
临床试验/JPRN-UMIN000013016
JPRN-UMIN000013016招募中2 期

Prospective study of efficacy and safety of preoperative transcatheter arterial chemolipiodolization with miriplatin for hepatocellular carcinoma.(Phase II study) - Phase II trial of preoperative Chemolipiodolization with miriplatin for hepatocellular carcinoma.

Second department of surgery, Dokkyo Medical University0 个研究点目标入组 100 人开始时间: 2014年1月30日最近更新:
适应症

试验速览

阶段
2 期
状态
招募中
发起方
入组人数
100

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
20years-old 至 ot applicable(—)
性别
All

入选标准

  • 未提供

排除标准

  • 1) Patients who have medical history of hypersensitivity of platinum-containing drug, iodine-containing drug and gelatine. 2) Patients with serious complications(Severe thyroid disease, Severe heart disease and the like.) 3) Patients with active double cancer. 4) Patients with bile duct invasion. 5) Pregnant and lactating females; males and females of childbearing age unless using effective contraception. 6) Patients without remarkable findings of A-V shunt and/or A-P shunt. 7) Tumor thrombosis in main portal vein or vena cava 8) Patients who are concluded to be inappropriate to participate in this study by their physicians

研究者

发起方
Second department of surgery, Dokkyo Medical University

相似试验